Drug Dosing in Renal Impairment

eGFR & CKD Staging

◡ eGFR Calculation Equations

CKD-EPI (Preferred for Staging)

Most accurate for classifying CKD stage and cardiovascular risk. Uses serum creatinine, age, sex. Reported by most modern laboratories as mL/min/1.73m².

Cockcroft-Gault (Preferred for Drug Dosing)

Used to calculate creatinine clearance (CrCl) for drug dosing decisions — especially for antibiotics, anticoagulants, renally-cleared drugs.

CG Formula: CrCl (mL/min) = [(140 − age) × weight] / (72 × serum creatinine mg/dL) × 0.85 if female
▶ Use actual body weight in obese patients (overestimates if lean body weight used). Use lowest of actual vs ideal for dosing safety.

MDRD (Older, Less Accurate)

4-variable MDRD less accurate at higher eGFR values (>60). Largely replaced by CKD-EPI. Still found in older references.

■ CKD G-Staging (eGFR mL/min/1.73m²)

G1 ≥90

G2 60–89

G3a 45–59

G3b 30–44

G4 15–29

G5 <15

G1 ≥90: Normal/high — CKD only if other markers present

G2 60–89: Mildly decreased

G3a 45–59: Mild-moderate decrease

G3b 30–44: Moderate-severe decrease

G4 15–29: Severely decreased — prepare for RRT

G5 <15: Kidney failure — dialysis/transplant

◆ Albuminuria Staging (ACR mg/mmol)

Stage	ACR (mg/mmol)	Description
A1	<3	Normal/mildly increased
A2	3–30	Moderately increased
A3	>30	Severely increased

CKD diagnosis requires: eGFR abnormality OR albuminuria OR other kidney damage markers for >3 months. Albuminuria drives cardiovascular and CKD progression risk independently of eGFR.

⚠ AKI vs CKD — Drug Dosing Implications

AKI: Use current creatinine to estimate real-time renal function. Adjust doses immediately. Function may recover — reassess frequently.

CKD: Use stable baseline creatinine. Drug accumulation risk is chronic and predictable. Adjust doses based on stable eGFR.

Dialysis (HD): Some drugs are removed by haemodialysis (e.g. aminoglycosides, vancomycin partially). Supplemental doses may be required after HD sessions. Check individual drug data — HD does NOT remove all drugs.

⚠ Drug Accumulation Risk — Why Renal Dosing Matters

Mechanism 1: Reduced Renal Clearance

Drugs primarily excreted by kidneys accumulate when GFR falls. Standard doses produce supratherapeutic plasma concentrations. Risk: toxicity (e.g. gentamicin nephrotoxicity/ototoxicity).

Mechanism 2: Active Metabolite Accumulation

Parent drug may be hepatically cleared but active/toxic metabolites are renally excreted. E.g. morphine-6-glucuronide (M6G) — causes CNS/respiratory depression in renal failure.

Mechanism 3: Pharmacodynamic Changes

Uraemia alters drug binding, CNS sensitivity, GI absorption. Patients may be more sensitive to standard doses even when plasma levels are not dramatically elevated (e.g. opioids, benzodiazepines).

Antibiotics in Renal Impairment

General principle: Many antibiotics are renally cleared. Failure to dose-adjust risks toxicity (aminoglycosides: nephrotoxicity, ototoxicity) or sub-therapeutic levels (ineffective treatment). Always check eGFR before prescribing.

💉 Antibiotic Dosing Reference Table

Antibiotic	eGFR >60	eGFR 30–60	eGFR 10–30	eGFR <10 / HD	Key Risks & Notes
Amoxicillin	Normal dose	Normal dose	Reduce dose	Reduce dose	Generally well tolerated; crystalluria at high doses
Co-amoxiclav	Normal	Caution eGFR <30	Reduce/extend interval	Avoid if eGFR <10	Clavulanate accumulates; GI toxicity risk
Ciprofloxacin	Normal	Normal	Halve dose	Avoid if eGFR <10	CNS toxicity, tendon rupture risk, QT prolongation
Trimethoprim	Normal	Use with caution	Reduce dose	Avoid if eGFR <15	Hyperkalaemia risk — blocks potassium excretion; avoid if K+ already elevated
Nitrofurantoin	Normal (UTI)	Caution eGFR 30–45	AVOID eGFR <45	AVOID	Ineffective (insufficient urinary concentration) + peripheral neuropathy toxicity
Meropenem	Normal	Reduce dose/extend	Further reduce	Significant reduction; HD supplement	CNS toxicity (seizures) at high doses in renal failure
Pip-Taz	Normal	Reduce dose	Reduce dose	Reduce; post-HD dose	Encephalopathy risk in severe CKD; electrolyte load (sodium)
Metronidazole	Normal	Normal	Normal	Metabolite accumulates	Metabolite accumulates but generally tolerated short-term; avoid prolonged use in severe CKD

⚠ Gentamicin — Critical Renal Considerations

AVOID in AKI unless no suitable alternative. If used, requires rigorous monitoring protocol.

Once-Daily Extended-Interval Dosing (Hartford Nomogram)

Dose 5–7 mg/kg IV once daily (uses concentration-dependent killing)
Obtain serum level 6–14 hours after first dose
Plot on Hartford nomogram to determine dosing interval (q24h / q36h / q48h)
Pre-dose (trough) level target: <1 mg/L — if above, extend interval or hold
In CKD: extend dosing interval based on eGFR

Toxicity Monitoring

Nephrotoxicity: rising creatinine, oliguria
Ototoxicity: tinnitus, hearing loss, vestibular disturbance (often irreversible)
Recheck renal function every 48–72 hours if prolonged course
Avoid concurrent nephrotoxins (NSAIDs, amphotericin, cisplatin)

💉 Vancomycin — AUC-Guided Dosing

Dosing Principle

Modern guidance: AUC/MIC-guided dosing target AUC 400–600 mg·h/L
Bayesian pharmacokinetic software preferred for calculations
Trough-only monitoring now considered inferior — but still used in many GCC hospitals
Trough target (traditional): 10–20 mg/L; severe MRSA: 15–20 mg/L

CKD/Renal Impairment

Renally cleared — extend dosing interval proportional to eGFR decline
eGFR <30: dose every 48–72 hours or by level
HD: variable removal depending on membrane type; check level post-HD
Monitor for nephrotoxicity (synergistic with aminoglycosides — avoid combination)
Red man syndrome (infusion rate related — not allergy)

Analgesics & Common Drugs in Renal Impairment

💊 Opioid Analgesics

Opioid	Recommendation in CKD/eGFR <30	Reason	Notes
Morphine	AVOID in CKD	M6G (morphine-6-glucuronide) accumulates → CNS & respiratory depression	Even single doses dangerous in dialysis patients
Codeine	AVOID eGFR <30	Codeine-6-glucuronide accumulates; unpredictable conversion to morphine	Also avoid in ultra-rapid metabolisers
Fentanyl	Preferred in renal failure	Inactive metabolites; minimal renal excretion	Patch/IV/intranasal; titrate carefully
Alfentanil	Preferred in severe renal failure	Hepatically metabolised; inactive metabolites	Short-acting; useful for procedures
Oxycodone	Use with caution	Active metabolite (oxymorphone) accumulates in CKD	Reduce dose & frequency; avoid in severe CKD
Hydromorphone	Use with caution	Metabolite (H3G) can cause neuroexcitatory effects	Reduce dose; prefer fentanyl if available

⚠ NSAIDs — Avoid in CKD

NSAIDs should be avoided in CKD patients due to multiple harmful mechanisms

Reduce renal prostaglandins → vasoconstriction → further GFR reduction
Sodium and water retention → hypertension, oedema, heart failure decompensation
Hyperkalaemia → dangerous in CKD patients already at risk
Acute-on-chronic kidney injury risk — especially with concurrent ACEi/ARB/diuretic
GCC context: NSAIDs are OTC — counsel patients explicitly to avoid

Paracetamol (Acetaminophen) is the preferred analgesic in CKD. Safe at recommended doses. Avoid excessive doses. Preferred over NSAIDs and opioids for mild-moderate pain.

◆ Gabapentinoids — Significant Dose Reduction Required

Gabapentin and pregabalin are renally excreted. In CKD, both accumulate rapidly, causing severe sedation, falls, and respiratory depression.

Drug	eGFR 30–60	eGFR 15–30	eGFR <15
Gabapentin	Reduce dose 50%	Reduce dose 75%	Max 300mg/day
Pregabalin	Reduce 50%	Reduce 75%	Max 75mg/day

Assess for dizziness, excessive sedation, confusion — early toxicity signs
Falls risk in elderly CKD patients particularly high
Dialysis patients: supplemental doses after HD (removed by dialysis)

⚠ Metformin — eGFR Thresholds Critical

eGFR	Action
>45	Continue — normal dose
30–45	Continue with caution — review dose, monitor closely
<30	STOP — contraindicated
Acute illness	HOLD — sick day rule (dehydration risk)
IV contrast	HOLD 48h pre/post contrast — lactic acidosis risk

Lactic acidosis is rare but life-threatening. Risk increases with renal impairment as metformin accumulates. In GCC, extremely high T2DM prevalence makes this a critical nursing consideration.

◆ DOAC Dose Adjustment in Renal Impairment

DOAC	Renal Excretion	Threshold / Action
Rivaroxaban	~33%	Reduce dose eGFR 15–49; AVOID <15
Apixaban	~27%	Use criteria (age/weight/Cr): AVOID if eGFR <15
Edoxaban	~50%	Reduce dose eGFR 15–50; AVOID <15
Dabigatran	~80%	AVOID if eGFR <30 (highest renal clearance)

Dabigatran is predominantly renally cleared — highest risk in CKD. Warfarin may be preferred over DOACs in dialysis patients (evidence base established). Always check anticoagulation protocol.

High-Risk Renally Cleared Drugs

The drugs below all have narrow therapeutic indices or significant toxicity risk in renal impairment. Frequent monitoring, dose adjustment, and nurse vigilance are essential.

⚠ Digoxin — Narrow Therapeutic Index

~80% renally excreted — accumulates significantly in CKD
Therapeutic range: 0.5–2.0 nmol/L (or 0.6–1.3 ng/mL for heart failure)
Dose reduction proportional to eGFR decline
Hypokalaemia and hypomagnesaemia potentiate digoxin toxicity even at therapeutic levels

Toxicity Signs (CRITICAL to recognise)

Cardiac: bradycardia, heart block, any arrhythmia
GI: nausea, vomiting, anorexia (often first signs)
Visual: yellow/green halos (xanthopsia), blurred vision
CNS: confusion, fatigue — especially in elderly

Check serum digoxin level, renal function, and electrolytes (K+, Mg²+) together. Level alone is insufficient — clinical context essential.

⚠ Allopurinol — Hypersensitivity Risk at Normal Doses

Renally excreted — accumulates in CKD → increased risk of allopurinol hypersensitivity syndrome (AHS)
AHS: severe rash, Steven-Johnson syndrome, TEN, hepatitis, eosinophilia — can be life-threatening

eGFR	Recommended Max Dose
>60	300mg/day (standard)
20–60	200mg/day
10–20	100mg/day
<10	100mg every 2 days or less
Dialysis	100mg after each dialysis

Prescribing full-dose allopurinol (300mg) to a patient with eGFR <20 significantly increases the risk of life-threatening hypersensitivity.

⚠ Lithium — Renal Clearance 95%

Lithium is almost entirely renally excreted. Any reduction in renal function — even transient AKI from dehydration — can rapidly produce lithium toxicity.

High-Risk Situations

AKI (even mild dehydration/gastroenteritis)
Concurrent NSAIDs (reduce renal lithium clearance)
Concurrent ACE inhibitors or ARBs
Diuretics (especially thiazides)
Sodium restriction or low-salt diet

Toxicity Signs

Mild: tremor, polyuria, nausea, diarrhoea
Moderate: ataxia, drowsiness, confusion, coarse tremor
Severe: seizures, coma, cardiac arrhythmias — MEDICAL EMERGENCY

Target level 0.6–1.0 mmol/L (therapeutic); >1.5 mmol/L = toxic; >2.0 mmol/L = severe toxicity. AVOID if eGFR <30.

◆ ACE Inhibitors / ARBs in CKD

Despite reducing eGFR slightly, ACEi/ARBs are recommended in CKD with proteinuria — they reduce progression and cardiovascular risk. The benefit outweighs a modest, expected eGFR decline.

Expected vs Concerning eGFR Change

Acceptable: Up to 20% eGFR fall after starting ACEi/ARB — stable and predictable
Concerning: >30% fall — consider renal artery stenosis or excessive volume depletion

Hyperkalaemia Management

Check K+ at 1–2 weeks after initiation or dose increase
K+ >6.0 mmol/L → withhold and review urgently
Avoid concurrent trimethoprim, NSAIDs, potassium supplements

Metoclopramide

Reduce dose in CKD — increased risk of extrapyramidal/dystonic side effects due to accumulation.

📋 High-Risk Drugs Quick Reference

Drug	Renal Excretion	Primary Risk in CKD	Monitoring	Action
Digoxin	80%	Arrhythmia, toxicity	Levels, K+, Mg²+, ECG	Reduce dose
Lithium	95%	Neurotoxicity, renal damage	Levels, renal function, TFTs	Avoid eGFR <30
Allopurinol	High	Hypersensitivity syndrome (AHS)	Rash, LFTs, FBC	Reduce dose by eGFR
Gentamicin	~99%	Nephrotoxicity, ototoxicity	Levels, creatinine, urine output	Avoid in AKI
Vancomycin	~90%	Nephrotoxicity, ototoxicity	AUC or trough levels	Extend interval
Dabigatran	80%	Bleeding (drug accumulation)	Renal function, anti-Xa/dTT	Avoid eGFR <30

Practical Nursing Application

⚠ SADMANS — Sick Day Rules

Counsel CKD patients to temporarily withhold these drug classes during acute illness with diarrhoea, vomiting, fever or poor fluid intake (dehydration → AKI risk):

Sulfonyl-ureas

Glibenclamide, Gliclazide

ACE Inhibitors

Ramipril, Lisinopril

Diuretics

Furosemide, Thiazides

Metformin

Glucophage

ARBs

Losartan, Valsartan

NSAIDs

Ibuprofen, Diclofenac

SGLT-2 Inhib.

Empagliflozin, Dapagliflozin

Advise patients to resume medications once they are eating, drinking and urinating normally. If in doubt, seek medical advice before restarting.

📋 Recognising Drug-Induced AKI

Causative Agent	Mechanism	Recognition
NSAIDs	Prostaglandin inhibition → renal vasoconstriction	Rising creatinine 1–5 days after starting
ACEi/ARBs	Efferent arteriole dilation → reduced GFR (worse if bilateral RAS)	>30% creatinine rise in first 2 weeks
Gentamicin	Direct tubular toxicity	Rising creatinine after 5–7 days; casts on urinalysis
Vancomycin	Oxidative tubular injury (synergistic with pip-taz)	Monitor creatinine, urine output
Contrast (IV)	Renal vasoconstriction + direct tubular toxicity	Creatinine peak 48–72h post contrast
Metformin	Does not cause AKI but accumulates in AKI → lactic acidosis	Lactic acidosis, confusion

◉ Drug Reconciliation on Admission

Step-by-Step Process

Obtain complete medication history (all prescriptions, OTCs, herbals)
Check admission eGFR/creatinine — record on drug chart
Cross-reference each drug against renal dosing requirements
Flag nephrotoxic drugs: NSAIDs, aminoglycosides, vancomycin, contrast
Check for renally-excreted drugs with narrow therapeutic index
Flag drugs requiring dose adjustment
Communicate concerns to prescriber before administration
Document findings in nursing notes and drug kardex

Key question for every drug: "Is this drug primarily renally excreted, and has the dose been adjusted for this patient's current eGFR?"

📖 Resources for Renal Drug Dosing

BNF (British National Formulary) — renal impairment appendix; free online bnf.nice.org.uk
Renal Drug Handbook (Ashley & Dunleavy) — gold standard reference for CKD/dialysis dosing
Renaldrugdatabase.com — comprehensive online database; tablet/dialysis specific
UpToDate — clinical decision support with renal dosing sections
Medscape Drug Reference — free app; renal dosing adjustments included
Local pharmacy team — clinical pharmacist input for complex cases
DHA/DOH formularies — region-specific guidance for GCC practice

⚠ When to Escalate

Creatinine rising >26 μmol/L within 48h or >50% from baseline — suspect AKI
Oliguria (<0.5 mL/kg/hr for >6 hours) despite adequate fluid status
Signs of drug toxicity: digoxin symptoms, opioid sedation/respiratory depression, gentamicin vestibular symptoms
K+ >5.5 mmol/L in patient on ACEi/ARB/trimethoprim
Unexpected confusion, falls, or sedation in CKD patient recently started on gabapentinoid
Patient taking NSAIDs/herbal remedies despite CKD diagnosis
Drug chart has no renal dose adjustment documented despite eGFR <30

Document, escalate to prescriber/senior nurse, and ensure the patient is assessed. Record time and response.

GCC Context & Exam Preparation

🌍 GCC-Specific Renal Drug Considerations

Epidemiological Context

CKD prevalence: 20–25% of diabetic patients in GCC progress to CKD — one of highest rates globally
Diabetes + Hypertension epidemic: Primary drivers of CKD in Saudi Arabia, UAE, Kuwait, Qatar, Bahrain, Oman
NSAID misuse: Ibuprofen/diclofenac widely available OTC; cultural acceptance of self-medication for pain — major nephrotoxicity concern
Contrast nephropathy: High utilisation of CT/MRI/angiography in GCC healthcare → CN-AKI risk; pre-procedure hydration protocols essential

Traditional & Herbal Nephrotoxicity

Aristolochic acid: Present in some traditional Chinese herbal medicines used in GCC communities — causes aristolochic acid nephropathy (irreversible fibrosis)
Al-qust (Costus): Used in some Gulf herbal traditions — renal toxicity reported
Heavy metal contamination in some traditional remedies — lead, mercury nephrotoxicity
Nursing action: Ask ALL patients about herbal/traditional medicine use on admission; report to team

🏗 Healthcare System Considerations

Aminoglycoside Use

Still used in resource-variable settings and some GCC public hospitals
Gentamicin is cost-effective and commonly stocked — nurses must know monitoring protocols
Ensure Hartford nomogram or equivalent protocol is available on ward

DHA / DOH Protocols

Dubai Health Authority (DHA) and Abu Dhabi Health Authority (DOH/SEHA) have specific formularies and renal dosing protocols
Always follow your facility-specific renal dosing guidelines when available
Metformin hold policy for contrast procedures is institutionally mandated
Vancomycin AUC-guided dosing increasingly adopted in GCC tertiary centres

SCFHS Pharmacology Exam Topics

Saudi Commission for Health Specialties (SCFHS) nursing exams test renal pharmacology extensively
Focus areas: eGFR staging, drugs to avoid in CKD, monitoring parameters, sick day rules

📋 DHA / DOH / SCFHS Exam — Key Revision Points

eGFR & CKD Stages

G1 ≥90 / G2 60–89 / G3a 45–59 / G3b 30–44 / G4 15–29 / G5 <15
CKD-EPI preferred for staging; Cockcroft-Gault for drug dosing
Albuminuria: A1 <3 / A2 3–30 / A3 >30 mg/mmol
Need >3 months for CKD diagnosis

Drugs to AVOID in CKD

NSAIDs — at any level of impairment
Morphine — avoid if eGFR <30 (M6G)
Codeine — avoid eGFR <30
Nitrofurantoin — avoid eGFR <45
Metformin — stop if eGFR <30
Lithium — avoid eGFR <30
Dabigatran — avoid eGFR <30

Monitoring Requirements

Gentamicin: Hartford nomogram, trough <1 mg/L
Vancomycin: AUC/MIC or trough monitoring
Digoxin: serum level + K+ + Mg²+ + ECG
Lithium: level + renal function + TFTs
ACEi/ARB: K+ at 1–2 weeks
Allopurinol: watch for rash (AHS)

Preferred Drugs in Renal Failure

Analgesia: Fentanyl, alfentanil (inactive metabolites)
Antibiotic: Metronidazole (safe, normal dose)
Pain/fever: Paracetamol (preferred over NSAIDs)
Anticoagulation in CKD: Warfarin (dialysis); Apixaban (least renal excretion)

Sick Day Rules (SADMANS)

S — Sulphonylureas
A — ACE inhibitors
D — Diuretics
M — Metformin
A — ARBs
N — NSAIDs
S — SGLT-2 inhibitors

⚙ Renal Drug Safety Checker

Enter the patient's eGFR and select a drug to receive dosing recommendation, monitoring requirements, alternatives, and counselling points.

Patient eGFR (mL/min/1.73m² or CrCl mL/min)

Select Drug

Dose Recommendation

Monitoring Required

Recommended Alternative

Patient Counselling Points

Drug Dosing in Renal Impairment GCC Nursing Guide